June 12 – 17, 2022
The regulations, safety and purity demands are extremely high for vaccine processes and likewise reflected in process development time and cost. Reducing time-to-market is key for pharmaceutical companies, hence saving lives and money, and therefore the need raised for systematic, general and efficient process development strategies (Hanke & Ottens, 2014). Despite the tremendous variation between vaccine purification processes, platform processes for similar types of vaccines could aid to generally accelerate the process development and would be beneficial in terms of knowledge, resources, costs and regulatory aspect. High throughput process development (HTPD) approaches can be used to establish platform processes. HTPD combines high throughput technologies and statistical or mechanistic modeling in an efficient manner. In particular mechanistic models, that aim to describe the real process based upon physical processes occurring, can be of great merit to extend the level of process understanding and thereby support in making decision regarding the process design (Pirrung et al., 2019).
Please click Download on the upper right corner to see the full abstract.
Daphne Keulen, Roxana Disela, Geoffroy Geldhof, Olivier Le Bussy, Martin Pabst, and Marcel Ottens, "Model-based process development for complex vaccine mixtures" in "Vaccine Technology VIII", Tarit Mukhopadhyay, Merck Research Laboratories, USA; Charles Lutsch, Sanofi Pasteur, France; Linda Hwee-Lin Lua, University of Queensland, Australia; Francesc Godia, Universitat Autònoma de Barcelona, Spain Eds, ECI Symposium Series, (2022). https://dc.engconfintl.org/vaccine_viii/108